About Jimena Vicencio
Articles by Jimena Vicencio, MD
Join Us for the Chicago Myeloma RoundtableMay 08, 2025
How Substance Use Impacts Cancer Care: Breaking the Stigma to Improve Patient OutcomesMay 07, 2025
Anxious About Your Myeloma Exams? You Are Not Alone: Learn What Scanxiety IsMay 06, 2025
Combining New and Traditional Therapies for AML and MDS TreatmentMay 06, 2025
Brexucabtagene Autoleucel for Relapsed/Refractory ALLMay 06, 2025
What is Transformed Follicular Lymphoma?Apr 30, 2025
Momelotinib May Reduce Transfusions and Improve Quality of LifeApr 30, 2025
From Diagnosis to Dialysis: When to Start Treatment for Kidney Disease?Apr 29, 2025
European Union Approves Linvoseltamab for Relapsed/Refractory Multiple MyelomaApr 29, 2025
Can Bone Marrow Fibrosis Be Reversed?Apr 28, 2025
Latest Advances in Glofitamab for LBCLApr 25, 2025
Investigating a New Oral Combination for Relapsed/Refractory CLL and Richter TransformationApr 25, 2025
Vibecotamab: A Potential Treatment Option for Myeloid Blood CancersApr 25, 2025
What are the Benefits of Elritercept for Myelofibrosis? Results from Phase 2 RESTORE TrialApr 24, 2025
Gemtuzumab Ozogamicin for Pediatric AMLApr 24, 2025
Golcadomide for Aggressive LymphomaApr 18, 2025
Want a Better Understanding of Clinical Trials? Start Here: Clinical Trial Endpoints GuideApr 10, 2025
Current Use of Tandem Transplant in MyelomaApr 09, 2025
Timing is Everything: New Research Might Change MDS Treatment ApproachApr 09, 2025
Assessing Racial and Ethnic Disparities and Outcomes in MyelofibrosisApr 04, 2025
What Works Better for AML: Intensive Chemotherapy or Venetoclax/HMAs?Apr 02, 2025
Fuel Your Health Webinar: Nutrition Strategies for Anemia and MDSApr 02, 2025
New AML Therapy: Pivekimab SunirineMar 31, 2025
New Chemo-Free Trials for Relapsed/Refractory LBCLMar 28, 2025
